The difference between multi-drug resistant cell line A549/Gem and its parental cell A549

Chinese-German Journal of Clinical Oncology

Volumn 8, Issue 4, 2009, Pages 190-194

  Wang, Weixia ^a   Liu, Xiaoqing ^a   Tang, Chuanhao ^a  

^a Beijing 307 Hospital   (China)

Author keywords

Gemcitabine; Gene; Multi drugresistance; Non smallcell lung cancer (NSCLC)

Indexed keywords

CD44V6 ANTIGEN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FLUOROURACIL; GELATINASE B; GEMCITABINE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MYC PROTEIN; NAVELBINE; NUCLEOSIDE DIPHOSPHATE KINASE NM23; OXALIPLATIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN P53; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN;

ARTICLE; CANCER RESISTANCE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL STRAIN; CELL STRAIN A549; CELL STRUCTURE; CONTROLLED STUDY; CROSS RESISTANCE; DNA CONTENT; DRUG SENSITIVITY; GENE EXPRESSION; GERM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION;

EID: 65449168366     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/s10330-009-0022-x     Document Type: Article

References (13)

1. Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res, 2004, 64: 3761-3766.
2. Situ ZQ, Wu JZ. Cell culture. Revised ed. Xi'an: International Books Publishing Company, 2004. 241-243, 367-370. 241-243,
3. Bepler G, Zheng Z, Gautam A, et al. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer, 2005, 47: 183-192.
4. Smid K, Bergman AM, Eijk PP, et al. Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. Nucleosides Nucleotides Nucleic Acids, 2006, 25: 1001-1007.
5. Hoon DS, Kitago M, Kim J, et al. Molecular mechanisms of metastasis. Cancer Metastasis Rev, 2006, 25: 203-220.
6. Krishnan K, Khanna C, Helman LJ. The molecular biology of pulmonary metastasis. Thorac Surg Clin, 2006, 16: 115-124.
7. Singhal S, Vachani A, Antin-Ozerkis D, et al. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: A review. Clin Cancer Res, 2005, 11: 3974-3986.
8. Sun Y. p53 and its downstream proteins as molecular targets of cancer. Mol Carcinog, 2006, 45: 409-415.
9. Iniesta P, Morán A, De Juan C, et al. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol Rep, 2007, 17: 217-223.
10. Swanton C, Futreal A, Eisen T. Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res, 2006, 12: 4377s-4383s.
11. Endoh H, Yatabe Y, Kosaka T, et al. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol, 2006, 1: 629-634.
12. Danesi R, Pasqualetti G, Giovannetti E, et al. The role of pharmacogenetics in adjuvant treatment of non-small cell lung cancer. J Thorac Oncol, 2007, 2: S27-S30.
13. Shimizu J, Horio Y, Osada H, et al. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology, 2008, 13: 510-517.